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683utility of statins in patients with PAD; a revision of the Adult
Treatment Panel III (ATP III) guidelines designates PAD
a “coronary heart disease risk equivalent,” and consensus
guidelines recommend statin therapy to target a low-density
lipoprotein (LDL) level of 100 mg/dl (2.59 mmol/l) for
“very high risk” patients (4,13). However, these recommen-
dations are based predominantly on data from patients with
claudication or population screening ankle-brachial indexes
(ABIs). Thus, the value of statin therapy for patients withCLI
is uncertain.
We hypothesized that statin therapy would be associated
with a reduced rate of major adverse cardiovascular and
cerebrovascular events (MACCE) and a reduced rate of
major amputation in patients with CLI. We tested this
hypothesis in a large cohort of patients with CLI who were
treated longitudinally at a multidisciplinary vascular center.PAD = peripheral arterial
diseaseMethods
Design. ThePAD-UCDRegistry comprises all patientswith
a clinical diagnosis of PAD who underwent diagnostic angi-
ography and/or therapeutic endovascular intervention at the
UC Davis Medical Center from 2006 to 2012. During this
interval, 3 vascular surgeons and 1 interventional cardiologist
performed all of the procedures.At the timeof data analysis, the
registry included 975 patients and 1,490 procedures. The study
protocol was approved by the Institutional ReviewBoard at the
University of California, Davis Medical Center.
Data collection and deﬁnitions. We identiﬁed patients
who had at least 1 presentation during the study period
for CLI, deﬁned as Rutherford class 4 to 6 disease (rest
pain, nonhealing ulceration due to arterial insufﬁciency, or
gangrene) (14). We retrospectively analyzed these patients’
data on the basis of a review of electronic medical record
documentation. We used pre- and post-procedure hospital
and clinic records to identify patient demographics, baseline
health status and medical management, clinical presentation,
vascular procedures, post-procedure management, and out-
comes. All records were reviewed by trained chart abstractors
and veriﬁed by a board-certiﬁed cardiologist. Patients were
categorized into the statin group if either their hospitaliza-
tion data or the most recent pre-procedure clinic visit indi-
cated current statin use. Other medication prescriptions
were determined based on the most recent pre-procedure
clinic visit. Baseline serum LDL levels were determined
using the most recent value within 6 months pre-procedure.
Routine practice at our institution during this period was
to schedule follow-up visits within 1 month after angio-
graphic procedures, then every 3 months for the ﬁrst year
and every 6 to 12 months thereafter. At these visits, patients
were assessed for clinical improvement, and those who had
interventions were evaluated with interval ABI measure-
ments and duplex ultrasonography.
Outcomes. The primary endpoint was a composite measure
ofMACCE, deﬁned as any death,MI, or stroke within 1 year
post-procedure. MI was deﬁned as symptoms of chestpressure and elevation of tro-
ponin with evidence of infarct by
stress imaging or coronary angi-
ography and ventriculography.
Stroke was deﬁned as focal neu-
rological deﬁcit lasting >24 h
with computed tomography or
magnetic resonance imaging evi-
dence of cerebral ischemic infarct
or intracerebral hemorrhage.
Secondary outcomes, all at 1
yearpost-procedure, includeddeath,
MI, stroke, subsequent ipsilateral
lower extremity bypass grafting,
and ipsilateral major amputation,
deﬁned as any amputation above
the level of the ankle joint. To
account for the competing hazard
of death among patients at high risk of needing amputation,
we also evaluated amputation-free survival as a composite
endpoint.
Lesion-speciﬁc secondary outcomes included primary,
primary assisted, and secondary patency of all lesions treated
with endovascular intervention. Loss of primary patency
was deﬁned as a velocity ratio of 2.0 as assessed by duplex
ultrasonography or endovascular or surgical reintervention
to the target vessel. Primary assisted patency was deﬁned as
patency after treatment for restenosis, and secondary
patency was deﬁned as overall patency after restenosis or
occlusion.
All outcomes were adjudicated from physician documen-
tation in the electronic medical record. To ensure that deaths
outside our institution were captured, patient vital status was
also veriﬁed using the Social Security Death Index.
Data analysis. Values of mean  SD were used to describe
continuous variables, and frequencies and percentages were
used for categorical variables. Continuous variables were
compared using the Wilcoxon rank sum test or analysis of
variance, and categorical values using the chi square or
Fisher exact test. All analyses were performed using Stata
version 11.2 (StataCorp LP, College Station, Texas).
We developed propensity scores to adjust for confounding
in statin use, deﬁned as the conditional probability of being
treated with a statin given a patient’s measured demographic
and clinical characteristics (15). To calculate the propensity
score for statin treatment, we developed a logistic model for
statin treatment using stepwise logistic regression analysis.
Baseline covariates in the model included age, sex, and race;
history of diabetes, coronary artery disease (CAD), MI,
hypertension, heart failure, stroke, carotid artery disease, or
chronic obstructive pulmonary disease; smoking status;
left ventricular ejection fraction (in 5% increments
from 10% to 65%); prescription of concomitant medi-
cations including angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, aspirin, and clopidogrel;
and year of procedure.
Table 1
Baseline Characteristics of Patients With
Critical Limb Ischemia
Variable
Statin
(n ¼ 246)
No Statin
(n ¼ 134) p Value
Age, yrs 69.0  13.3 68.0  13.9 0.4
Male 145 (59) 68 (51) 0.1
Race/ethnicity 0.7
Caucasian 179 (73) 98 (73)
Hispanic 29 (12) 20 (15)
African American 31 (13) 13 (10)
Asian 7 (3) 3 (2)
BMI, kg/m2 27.4  6.2 26.6  6.5 0.2
Smoker, former or
current
168 (69) 87 (66) 0.5
CHF 79 (33) 36 (27) 0.3
DM 167 (68) 65 (50) <0.001
GFR, ml/min 59.8  39.4 61.2  40.8 0.8
HTN 221 (90) 103 (77) <0.001
SBP, mm Hg 134  23 132  23 0.99
CAD 144 (59) 40 (31) <0.001
History of MI 72 (29) 12 (9) <0.001
Ejection fraction, % 53.1  17.3 52.6  18.5 0.9
History of stroke/TIA 58 (24) 17 (13) 0.01
History of malignancy 30 (12) 14 (10) 0.6
COPD 40 (16) 16 (12) 0.2
History of AAA 10 (4) 4 (3) 0.6
History of carotid artery
stenosis
42 (18) 5 (4) <0.001
History of contralateral
amputation
14 (10) 37 (15) 0.2
Cholesterol levels, mg/dl
Total 142  41 167  60 0.001
LDL 75  28 96  40 <0.001
HDL 39  18 35  17 0.3
TG 130  65 145  84 0.2
HbA1c, % 7.9  2.2 7.8  2.1 0.9
ACE inhibitor or ARB 162 (66) 57 (43) <0.001
Beta-blocker 154 (63) 47 (35) <0.001
Aspirin 225 (91) 117 (87) 0.2
Clopidogrel 168 (68) 77 (57) 0.04
Other lipid medications* 31 (13) 12 (9) 0.6
Rutherford score 0.8
4 38 (15) 22 (16)
5 177 (73) 95 (70)
6 29 (12) 18 (13)
ABIy 0.48  0.24 0.48  0.27 0.9
TBI 0.19  0.17 0.18  0.20 0.7
Values are mean  SD or n (%). *Other lipid medications included ﬁbrate, ﬁsh oil, niacin, and
ezetimibe. yExcluding subjects with ABI >1.4, for whom TBI was also measured.
AAA ¼ abdominal aortic aneurysm; ABI ¼ ankle-brachial index; ACE ¼ angiotensin converting
enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CAD ¼ coronary artery
disease; CHF ¼ congestive heart failure; COPD ¼ chronic obstructive pulmonary disease;
DM ¼ diabetes mellitus; GFR ¼ glomerular ﬁltration rate; HBA1c ¼ hemoglobin A1c; HDL ¼ high-
density lipoprotein; HTN ¼ hypertension; LDL ¼ low-density lipoprotein; MI ¼myocardial infarction;
SBP ¼ systolic blood pressure; TG ¼ triglyceride; TIA ¼ transient ischemic attack; TBI ¼ toe brachial
index.
Figure 1 Rate of Statin Prescription Over Time
The percentage of patients with critical limb ischemia prescribed a statin
medication by year, 2006 to 2012 (p ¼ 0.07 for trend).
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684Multiple methodologies were used to validate the pro-
pensity model. The C statistic of the model was 0.79. To
assess covariate balance across the distribution of propensity
scores, we visually compared propensity score overlap with
kernel density plots (Online Fig. 1). We also calculated theodds of treatment with a statin for each of the covariates
within a given quintile and then used Mantel-Haenszel es-
timates of common odds ratios to calculate summary odds
ratios across all quintiles before and after propensity
adjustment (16). Standardized mean differences were also
calculated for each covariate and were veriﬁed to be balanced
for each covariate after adjustment (Online Table 1) (17). To
determine the best estimate with observational data of the
treatment effect of statin use, proportional hazards marginal
structural models were then developed via weighted regres-
sion with inverse probability of treatment weighting using
the propensity score (18,19). As a sensitivity analysis, pro-
pensity modeling was also performed using nearest-neighbor
matching, and results were obtained qualitatively similar to
those of the inverse probability of treatment weighting
model. To account for the possibility that censoring patients
at the ﬁrst event could obscure effects on other competing
risks, we also conducted a competing risks analysis using the
method of Fine and Gray (20).
To analyze lesion-level outcomes, we stratiﬁed inter-
ventions according to the anatomic level of disease (femo-
ropopliteal vs. infrapopliteal).We then usedCox proportional
hazard models to estimate hazard ratios (HRs) for the effect
of statin medications on restenosis and target vessel revascu-
larization. We included lesion length, proximal vessel refer-
ence diameter, diabetes, sex, smoking status, estimated
glomerular ﬁltration rate, and, for femoropopliteal lesions,
stent placement as multivariable predictors of restenosis.
To study the relationship of baseline LDL level to out-
comes, patients were stratiﬁed into 4 LDL subgroups based
on ATP III guidelines: <70 mg/dl, 70 to 100 mg/dl, 100 to
130 mg/dl, and >130 mg/dl (<1.81 mmol/l, 1.81 to 2.59
mmol/l, 2.59 to 3.36 mmol/l, and >3.36 mmol/l) (13). To
minimize bias in the outcomes due to missing LDL data,
multiple imputation with 10 imputations was used.
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685MACCE and mortality were then analyzed using Cox
proportional hazard modeling that included LDL level as an
additional covariate in a model that also adjusted for other
baseline demographic factors among patients treated with
statin medications.Results
Study population. A total of 380 patients presented with
CLI and underwent peripheral angiography during the study
period (Table 1). Median follow-up time derived from
Kaplan-Meier estimates was 409 days. With respect to the
primary outcome of MACCE, 4 patients (3.0%) in the no
statin group and 9 patients (3.7%) in the statin group were lost
to follow-up (p ¼ 0.96). Overall, 65% of the patients were
taking a statin at baseline, a percentage that ranged from 58%
for patients entering the study in 2006 to 71% in 2012
(p ¼ 0.07 for trend) (Fig. 1). More than 40% of the patients
were female; we previously reported differences in the pre-
sentation and outcomes for this cohort on the basis of sex,
including a higher rate of MACCE for women (21). Simva-
statin and atorvastatin were the 2 most frequently prescribed
statins, and together accounted for 73% of the prescribedFigure 2 Total Cholesterol and LDL Levels by Statin Use
Baseline total cholesterol (p < 0.01) (A) and LDL (p < 0.01) (B) levels were lower
in the group prescribed statin medications. LDL ¼ low-density lipoprotein.statins. Additional lipid-lowering medications were pre-
scribed in <15% of patients. Among patients not taking a
statin, only 6 (4%) had a documented contraindication.
Patients prescribed statin medications had higher rates of
baseline medical comorbidities, including a higher preva-
lence of diabetes mellitus, hypertension, CAD, and carotid
artery stenosis (Table 1). Patients prescribed a statin were
also more likely to have a history of MI or stroke/transient
ischemic attack. Other baseline differences between the 2
groups included a higher rate of concomitant medical
therapies among patients receiving statins including beta-
blockers, angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers, and clopidogrel. Patients
taking a statin medication also had lower baseline levels of
total cholesterol and LDL (Fig. 2). Rates of baseline
comorbidities including a history of diabetes and CAD did
not show signiﬁcant trends by year (p ¼ 0.21 and p ¼ 0.73,
respectively). The angiographic characteristics of the 2
groups were similar, with the exception of a higher rate of
multilevel stenosis (deﬁned as at least 1 stenosis >50% in
both a femoropopliteal vessel and an infrapopliteal vessel) in
the statin group (Table 2).
Outcomes by statin use. The event rates and HRs for all
clinical outcomes are summarized in Table 3. Patients pre-
scribed statin therapy had lower absolute event rates for all
outcomes despite greater baseline comorbidities. The pro-
pensity model showed good balance in adjusted variables,
with no signiﬁcant difference in the pooled odds of statin
prescribing after propensity weighting for all measured
covariates (Fig. 3). After adjustment, MACCE (HR: 0.53,
95% conﬁdence interval [CI]: 0.28 to 0.99) (Fig. 4A) and
mortality (HR: 0.49, 95% CI: 0.24 to 0.97) (Fig. 4B) were
lower in the statin group. Rates of MI (HR: 0.48, 95% CI:
0.16 to 1.44), stroke (HR: 0.18, 95% CI: 0.02 to 1.78), and
amputation (HR: 0.68, 95% CI: 0.32 to 1.39) did not differ
signiﬁcantly, but all trended in a direction favoring statinTable 2
Lower Extremity Angiographic Characteristics of
Patients With and Without Statin Use
Statin
(n ¼ 246)
No Statin
(n ¼ 134) p Value
Level of disease*
Aortoiliac 54 (29) 33 (31) 0.7
Femoropopliteal 188 (82) 93 (73) 0.06
Infrapopliteal 205 (91) 105 (86) 0.2
Multilevel stenosisy 161 (68) 75 (57) 0.03
Chronic total occlusion
Aortoiliac 22 (12) 19 (18) 0.2
Femoropopliteal 114 (50) 60 (47) 0.7
Infrapopliteal 205 (91) 105 (86) 0.2
Lower extremity runoff 0.3
0 32 (15) 19 (16)
1–2 159 (73) 77 (66)
3 26 (12) 20 (17)
Values are n (%). *Level of disease was deﬁned as >50% stenosis within a given segment. The
totals are >100% because a given patient could have stenoses at multiple levels. yDeﬁned as at
least 1 stenosis >50% in both a femoropopliteal vessel and an infrapopliteal vessel.
Table 3 1-Year Outcome Rates and Unadjusted and Adjusted Hazard Ratios
Variables
Outcomes Rates* Unadjusted IPTW Adjusted
No Statin
(n ¼ 134)
Statin
(n ¼ 246) HR (95% CI) p Value HR (95% CI) p Value
Cardiac events
Death 27 (21) 35 (15) 0.69 (0.42–1.14) 0.1 0.49 (0.24–0.97) 0.04
MI 7 (6) 9 (5) 0.69 (0.26–1.85) 0.4 0.48 (0.16–1.44) 0.2
Stroke 3 (3) 1 (1) 0.18 (0.02–1.72) 0.2 0.18 (0.02–1.78) 0.1
MACCE 31 (23) 43 (18) 0.73 (0.46–1.16) 0.2 0.53 (0.28–0.99) 0.048
Lower extremity bypass 22 (18) 43 (18) 0.96 (0.57–1.62) 0.9 1.17 (0.61–2.24) 0.6
Amputation 19 (18) 25 (12) 0.70 (0.39–1.27) 0.2 0.68 (0.32–1.39) 0.3
Death/amputation 41 (35) 56 (27) 0.73 (0.49–1.09) 0.1 0.59 (0.35–0.98) 0.04
Values are n (%). *Raw number of events (Kaplan-Meier estimated percentage).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; IPTW ¼ inverse probability of treatment weighting; MACCE ¼major adverse cardiovascular and cerebrovascular events (myocardial infarction, stroke, or death);
MI ¼ myocardial infarction.
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686use. The risk of death or major amputation was also
signiﬁcantly decreased in those prescribed statins (HR: 0.53,
95% CI: 0.35 to 0.98) (Fig. 4C). There was no association
between statin use and rates of lower extremity bypass,
which were 18% at 1 year in both groups. Outcomes using aFigure 3 ORs of Statin Use by Baseline Demographics
(A) Before propensity weighting, signiﬁcant differences in baseline patient characteristics w
odds ratios for all measured covariates cross 1.0. ACE ¼ angiotensin-converting enzyme;
conﬁdence interval; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular ﬁcompeting risks analysis showed similar point estimates for
the relationships between statin use and MI, stroke, bypass,
and major amputation (Online Table 2).
Of the overall cohort, 295 patients (78%) underwent
endovascular intervention for limb salvage at the time ofere associated with statin use. (B) After adjustment, 95% conﬁdence intervals of the
ASA ¼ aspirin; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CI ¼
ltration rate; HTN ¼ hypertension; MI ¼ myocardial infarction; OR ¼ odds ratio.
Figure 4
Statin Use and Major Adverse Cardiovascular and
Cerebrovascular Events, Mortality, and
Amputation-Free Survival
Kaplan-Meier curves to 1 year after procedure showing the proportion free of major
adverse cardiovascular and cerebrovascular events (myocardial infarction, stroke,
or death; log rank, p < 0.05) (A); death (p < 0.05) (B), and death or amputation
(p < 0.05) (C). All curves are after propensity weighted adjustment.
Figure 5 Statin Use and Patency of Infrapopliteal Lesions
Kaplan-Meier curves to 1 year after angiography showing proportion free of loss of
primary patency (log rank, p ¼ 0.5) (A); primary assisted patency (p ¼ 0.04) (B);
and secondary patency (p ¼ 0.02) (C).
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687baseline angiography, whereas 23 patients (6%) underwent
major amputation and 38 patients (10%) underwent lower
extremity bypass grafting as initial management. The overall
procedural success rates for endovascular interventions weresimilar in both groups. The mean gain in ABI post-
procedure was 0.45  0.26 in the statin group and 0.39 
0.19 in the no statin group (p ¼ 0.2). Among infrapopliteal
lesions, statin use was associated with improved patency at
1 year (Fig. 5). Using Cox proportional modeling, statin
use was associated with a nonsigniﬁcant improvement in
Table 4
Lesion Outcomes Among Patients Undergoing
Endovascular Interventions
Statin, % No Statin, % Adjusted HR*
Femoropopliteal lesions
Primary patency 55 53 0.87 (0.50–1.50)
Primary assisted patency 73 67 0.62 (0.31–1.30)
Secondary patency 84 69 0.50 (0.22–1.30)
Infrapopliteal lesions
Primary patency 62 52 0.84 (0.50–1.42)
Primary assisted patency 78 57 0.50 (0.26–0.96)
Secondary patency 83 59 0.45 (0.22–0.89)
Outcomes are listed as Kaplan-Meier event rates at 1 year. *Adjusted HR is displayed at the
adjusted estimate with 95% conﬁdence intervals in parentheses. Multivariable adjustment included
for lesion length, proximal vessel reference diameter, diabetes, sex, smoking status, and estimated
glomerular ﬁltration rate. Femoropopliteal lesions were also adjusted for stent placement.
HR ¼ hazard ratio.
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688primary patency and signiﬁcantly improved primary assisted
patency and secondary patency of infrapopliteal lesions
(Table 4). These results remained signiﬁcant after multi-
variable adjustment. There was no signiﬁcant effect of sta-
tins on 1-year patency of femoropopliteal lesions. These
results suggest that the lower amputation rates among pa-
tients treated with statins may be due in part to improved
infrapopliteal vessel patency after endovascular intervention.
Outcomes by LDL level. We also explored the relation-
ship between LDL levels and MACCE among patients
prescribed statin medications. Among patients treated with
statins, the group with baseline LDL levels >130 mg/dl
had the highest unadjusted 1-year event rate (22%). After
multivariable adjustment including age, sex, history of MI,
diabetes, and carotid disease, LDL levels of 100 to 130 mg/dl
(HR: 0.51, 95%CI: 0.32 to 0.80), 70 to 100mg/dl (HR: 0.54,
95% CI: 0.36 to 0.83), and <70 mg/dl (HR: 0.71, 95% CI:
0.48 to 1.05) were each associated with a decreased HR of
MACCE relative to patients taking statin medications but
with baseline LDL values >130 mg/dl. Similar results were
observed for composite death and amputation among patients
treated with statins. Among patients not treated with statins,
there was also a qualitatively similar relationship between
LDL levels and MACCE.
Discussion
This study has 3 major ﬁndings. First, we report the prev-
alence of statin use in a cohort of CLI patients treated at a
tertiary care center and a trend toward increasing statin use
over time. Second, statin use was associated with decreased
subsequent risk MACCE (primarily due to decreased
mortality), increased likelihood of amputation-free survival,
and improved patency of infrapopliteal lesions. Third, we
found that lower LDL levels were associated with a
decreased risk of MACCE and mortality. To our knowl-
edge, this is the ﬁrst study in CLI patients to investigate the
relationship between statin use and MACCE.
Rates of statin use in CLI remain low. Our data on the
rates of statin use in PAD in general and CLI in particular
extend previous ﬁndings on this subject. Subherwal et al.(22) recently reported on trends in statin use in a general
PAD population at the time of diagnosis during the period
2000 to 2007 using Danish nationwide administrative reg-
istries. The overall statin use rate in our population (65%) is
higher than the 56% rate that they reported for patients
without CAD and similar to the rate for patients with both
PAD and CAD. Our data show a similar, although not
statistically signiﬁcant, trend toward higher statin use over
time. Given the lack of signiﬁcant increases over time of
other indications for statin therapy, this may indicate
improving quality of care or increasing awareness of PAD as
an indication for statin therapy. Previous reports in the CLI
population have indicated even lower rates of statin use,
ranging from 23% to 49% (23–25). In contrast, estimates of
statin use rates in patients with CAD range from approxi-
mately 68% to 78% (26–28). Further education and
awareness of the beneﬁts of statin use among patients with
CLI will be necessary to increase the rates of medication
prescription. Consistent with this goal, statin prescription
was recently included as a core performance measure for the
treatment of patients with PAD (29).
Further support for statin therapy in CLI. Our results
provide further evidence of statin therapy for patients with
CLI. The strongest evidence underlying the American
College of Cardiology and American Heart Association
recommendations of statin therapy derive from subgroup
analysis of the Heart Protection Study, which included
primarily patients with a low baseline ABI or stable clau-
dication (12,30). More recently, a large prospective, obser-
vational cohort study in the Netherlands demonstrated lower
all-cause and cardiac mortality in statin users with PAD
(31,32). However, these studies were conducted in general
PAD populations and included only very small numbers of
patients with CLI.
A small number of observational studies of CLI patients
have reported outcomes by statin use with mixed results.
Aiello et al. (23) recently studied patients undergoing endo-
vascular therapy for CLI and reported 24-month results
showing improved vessel patency, limb salvage, and survival
with statin use, but the authors did not consider MACCE.
Other studies have yielded conﬂicting results on the effect of
statins on graft patency, limb salvage, and mortality among
patients with CLI undergoing surgical bypass (24,25,33–35).
Our results contribute to this developing body of literature
by studying outcomes in a large representative cohort of
CLI patients with and without bypass grafts, whether or not
they underwent intervention. Unlike previous studies, we
report MACCE, capturing important outcomes that might
be neglected if only patency or mortality was studied. We also
present lesion results divided by anatomic site. The efﬁcacy of
statins in promoting patency of infrapopliteal vessels may be
related to the smaller caliber of these arteries and may partially
explain the effects of statins on reduced amputation rates.
Higher LDL levels associated with increased MACCE in
CLI. Our data also begin to explore the relationship be-
tween LDL levels and clinical outcomes in CLI patients.
JACC Vol. 63, No. 7, 2014 Westin et al.
February 25, 2014:682–90 Lower Major Adverse Events With Statins in Limb Ischemia
689The American College of Cardiology/American Heart
Association and ATP III guidelines recommend LDL goals
on the basis of the cardiovascular risk associated with PAD
and the evidence of LDL treatment goals in CAD. Feringa
et al. (31) strengthened the evidence for lower LDL treat-
ment targets in the general PAD population by reporting
progressively increasing mortality with higher LDL levels.
In CLI patients, Aiello et al. (23) reported baseline
cholesterol and LDL levels in their statin and control
groups, yet total cholesterol and LDL levels did not differ
between the groups. Our results provide the ﬁrst evidence
that higher levels of LDL are associated with increased rates
of mortality and MACCE in CLI patients, a population
with an already increased baseline risk. Future studies should
continue to investigate the optimal target level of LDL
among this high-risk group of patients.
Study limitations. First, we document a single-institution
experience at a tertiary care facility; patterns of care and
disease may differ at other sites of care. Also, as with all
observational studies, the reported associations may not
represent underlying causality. Our use of propensity score
weighting balanced the cohorts and reduced the effect of
measured confounding variables on our outcomes, although
it cannot account for unmeasured confounding variables.
Statin use may be a marker for quality of or access to care,
which could not be assessed with our study design. How-
ever, we included numerous measured covariates and
demonstrated excellent balance after propensity weighting.
We also used multiple methodologies to verify the adequacy
of adjustment for differences in baseline covariates as well as
sensitivity analyses that were consistent with our overall
results.
Similarly, the duration of statin therapy and compliance
could not be quantiﬁed in this study, and it is possible that
an increasing number of patients began taking statin med-
ications during follow-up. We also found an average LDL
level of only 96 mg/dl in the group not taking statins, despite
low rates of use of other lipid medications, which may
indicate that some patients were using statins but dis-
continued use before angiography. Crossover to statin use,
ceasing statin use either before baseline or during the study,
or noncompliance would not negatively affect the validity of
our ﬁndings, but instead strengthen our reported effect size
of statin use on subsequent MACCE. Given the existing
support for statin use in claudicants, we believe that evidence
of statin therapy in CLI should be interpreted as support for
continuous statin therapy beginning at the time of any PAD
diagnosis.
Although the majority of the endpoints were driven by a
decrease in overall mortality, we believe that the composite
endpoints of MACCE and death or major amputation are
useful because they are common, clinically meaningful
endpoints. Not ascertaining the cause of death, along with
losing patients to follow-up, limits our analyses. However,
previous studies have found that the majority of deaths in
patients with CLI are due to cardiovascular causes (36,37).That our results, like those of the PREVENT III (Project
or Ex-Vivo vein graft Engineering via Transfection III)
study, indicate a difference in mortality but not in sublethal
vascular events may indicate effective prevention of fatal
strokes and MIs. Low overall event rates for amputations
and nonfatal MIs and strokes, however, limit our power to
detect differences in these secondary outcomes.Conclusions
This study extends our understanding of the effects of statin
therapy in PAD and CLI, in particular. The improved rates
of 1-year MACCE with statin use strengthens the evidence
supporting the guideline recommendations of statin therapy
for all PAD patients, including those with even the most
advanced stages of disease. Although our data on statin use
rates compare favorably with previously published values,
statins remain an underused therapy (38). Our ﬁnding of
superior outcomes for patients with lower LDL levels also
provides support for the use of LDL as a treatment target in
patients with PAD. Future studies should determine the
optimal statin type and dose, further explore potential
treatment targets including LDL for statins in PAD pa-
tients, and investigate barriers to more widespread use of
statins among patients with CLI.Reprint requests and correspondence: Dr. John R. Laird,
Vascular Center, UC Davis Medical Center, 4860 Y Street, Suite
3400, Sacramento, California 95817. E-mail: john.laird@ucdmc.
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